We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
Tilray Brands, Inc. (TLRY - Free Report) ended the recent trading session at $4.50, demonstrating a -1.53% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.71%. Elsewhere, the Dow saw a downswing of 0.79%, while the tech-heavy Nasdaq depreciated by 1.03%.
Prior to today's trading, shares of the company had lost 1.51% lagged the Medical sector's gain of 4.16% and the S&P 500's gain of 2.72%.
The upcoming earnings release of Tilray Brands, Inc. will be of great interest to investors. Meanwhile, the latest consensus estimate predicts the revenue to be $268.23 million, indicating a 28.03% increase compared to the same quarter of the previous year.
TLRY's full-year Zacks Consensus Estimates are calling for earnings of -$0.42 per share and revenue of $1.1 billion. These results would represent year-over-year changes of +61.47% and +20.56%, respectively.
Investors should also note any recent changes to analyst estimates for Tilray Brands, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 3.48% fall in the Zacks Consensus EPS estimate. Currently, Tilray Brands, Inc. is carrying a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 91, finds itself in the top 37% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors
Tilray Brands, Inc. (TLRY - Free Report) ended the recent trading session at $4.50, demonstrating a -1.53% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.71%. Elsewhere, the Dow saw a downswing of 0.79%, while the tech-heavy Nasdaq depreciated by 1.03%.
Prior to today's trading, shares of the company had lost 1.51% lagged the Medical sector's gain of 4.16% and the S&P 500's gain of 2.72%.
The upcoming earnings release of Tilray Brands, Inc. will be of great interest to investors. Meanwhile, the latest consensus estimate predicts the revenue to be $268.23 million, indicating a 28.03% increase compared to the same quarter of the previous year.
TLRY's full-year Zacks Consensus Estimates are calling for earnings of -$0.42 per share and revenue of $1.1 billion. These results would represent year-over-year changes of +61.47% and +20.56%, respectively.
Investors should also note any recent changes to analyst estimates for Tilray Brands, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 3.48% fall in the Zacks Consensus EPS estimate. Currently, Tilray Brands, Inc. is carrying a Zacks Rank of #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 91, finds itself in the top 37% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.